Arrêt de service lundi 11 juillet de 12h30 à 13h : tous les sites du CCSD (HAL, EpiSciences, SciencesConf, AureHAL) seront inaccessibles (branchement réseau à modifier)
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study.

Abstract : BACKGROUND: Neurotrophins play a central role in the development and maintenance of the nervous system. However, neurotrophins can also modulate B and T cell proliferation and activation, especially via autocrine loops. We hypothesized that both serum and lymphocytic neurotrophin levels may be deregulated in systemic Lupus erythematosus (SLE) and may reflect clinical symptoms of the disease. METHODS: Neurotrophins in the serum (ELISA tests) and lymphocytes (flow cytometry) were measured in 26 SLE patients and 26 control subjects. Th1 (interferon-γ) and Th2 (IL-10) profiles and serum concentration of BAFF were assessed by ELISA in the SLE and control subjects. FINDINGS: We have demonstrated that both NGF and BDNF serum levels are higher in SLE patients than healthy controls (p=0.003 and p<0.001), independently of Th1 or Th2 profiles. Enhanced serum NT-3 levels (p=0.003) were only found in severe lupus flares (i.e. SLEDAI ≥ 10) and significantly correlated with complement activation (decreased CH 50, Γ=-0.28, p=0.03). Furthermore, there was a negative correlation between serum NGF levels and the number of circulating T regulatory cells (Γ=0.48, p=0.01). In circulating B cells, production of both NGF and BDNF was greater in SLE patients than in healthy controls. In particular, the number of NGF-secreting B cells correlated with decreased complement levels (p=0.05). One month after SLE flare treatment, BDNF levels decreased; in contrast, NGF and NT-3 levels remained unchanged. CONCLUSION: This study demonstrates that serum and B cell levels of both NGF and BDNF are increased in SLE, suggesting that the neurotrophin production pathway is deregulated in this disease. These results must be confirmed in a larger study with naive SLE patients, in order to avoid the potential confounding influence of prior immune-modulating treatments on neurotrophin levels.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Philippe Sindou Connectez-vous pour contacter le contributeur
Soumis le : vendredi 15 novembre 2013 - 15:51:21
Dernière modification le : dimanche 26 juin 2022 - 05:59:53

Lien texte intégral



Anne-Laure Fauchais, Marie-Claude Lise, Pierre Marget, François-Xavier Lapeybie, Holy Bezanahary, et al.. Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study.. PLoS ONE, Public Library of Science, 2013, 8 (11), pp.e79414. ⟨10.1371/journal.pone.0079414⟩. ⟨hal-00904959⟩



Consultations de la notice